Precision oncology using a clinician-directed, tailored approach to molecular profiling.

Michael LamBen TranSophie BeckJeanne TieDishan HerathJames WhittleEdmond M KwanStephen B FoxAndrew FellowesSumitra AnandaLara LiptonPeter GibbsMark A RosenthalJayesh Desai

Published in: Asia-Pacific journal of clinical oncology (2017)

A clinician-directed, tailored approach to the use of MP is feasible, resulting in 11% of patients enrolled onto molecularly matched trials.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
palliative care
smoking cessation
peritoneal dialysis
patient reported outcomes